Added to YB: 2026-08-26
Pitch date: 2026-08-20
DXCM [neutral]
DexCom, Inc.
-0.5%
current return
Author Info
No bio for this author
Company Info
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Market Cap
$34.8B
Pitch Price
$89.61
Price Target
N/A
Dividend
N/A
EV/EBITDA
23.94
P/E
36.41
EV/Sales
6.90
Sector
Health Care Equipment and Supplies
Category
value
The market punishes, my algorithm hunts: 17 potential opportunities in the S&P 500 - DexCom, Inc.
DXCM (quick overview): Algorithm flags DXCM (Score 83) as excessively punished: profit +84% while stock -16%. Screens on best-in-class 43% ROIC (rising), minimal debt, strong cash gen in a structurally growing CGM market. Risks: Abbott competition and GLP-1 weight-loss drugs potentially shrinking type 2 diabetes long term.
Read full article (1 min)